Single-dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P4502C19 (CYP2C19) activity

Therapeutic Drug Monitoring

Volumn 19, Issue 4, 1997, Pages 371-374

  Yasui, Norio ^a   Otani, Koichi ^a   Ohkubo, Tadashi ^a   Osanai, Takako ^b   Sugawara, Kazunobu ^a   Chiba, Kan ^c   Ishizaki, Takashi ^c   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b Goshogawara City Hospital   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Cytochrome P4502C 19; Pharmacodynamics; Pharmacokinetics; S mephenytoin4 hydroxylation; Triazolam

Indexed keywords

CYTOCHROME P450; DIAZEPAM; MEPHENYTOIN; NITRAZEPAM; TRIAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL PROTOCOL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; TABLET;

ADJUVANTS, ANESTHESIA; ADMINISTRATION, ORAL; ADULT; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIXED FUNCTION OXYGENASES; PSYCHOMOTOR PERFORMANCE; TIME FACTORS; TRIAZOLAM;

EID: 0031405810     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199708000-00001     Document Type: Article

References (17)

1. Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS. Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia. Drugs 1981;22:81-110.
2. Garzone PD, Kroboth PD: Pharmacokinetics of newer benzodiazepines. Clin Pharmacokinet 1989;16:337-364.
3. Phillips JP, Antal EJ, Smith RB. A pharmacokinetic drug interaction between erythromycin and triazolam. J Clin Psychopharmacol 1986;6:297-299.
4. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
5. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-607.
6. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993;3:61-70.
7. Wright CE, Lasher-Sisson TA, Steenwyk RC, Swanson CN. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992;12:103-106.
8. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-248.
9. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-409.
10. Bertilsson L, Henthorn T, Sanz E, Tybring G, Säwe J, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348-355.
11. Sohn D-R, Kusaka M, Ishizaki T, Shin S-G, Jang I-J, Chiba K. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992;52:160-169.
12. Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J. Absorption rate, blood concentrations, and early response to oral chlordiazepoxide. Am J Psychiatry 1977;134:559-562.
13. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Eigen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76(suppl 334):11-100.
14. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 1994;269:15,419-422.
15. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4: 285-299.
16. Ochs HR, Greenblatt DJ, Burstein ES. Lack of influence of cigarette smoking on triazolam pharmacokinetics. Br J Clin Pharmacol 1987;23:759-763.
17. Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994;4:209-228.